Cargando…

Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus

Bacterial infections remain the leading killer worldwide which is worsened by the continuous emergence of antibiotic resistance. In particular, methicillin-sensitive (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and the latter can be difficult to treat. The traditional...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Yanmin, Liu, Alexander, Vaudrey, James, Vaiciunaite, Brigita, Moigboi, Christiana, McTavish, Sharla M., Kearns, Angela, Coates, Anthony
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333121/
https://www.ncbi.nlm.nih.gov/pubmed/25692771
http://dx.doi.org/10.1371/journal.pone.0117664
_version_ 1782357980215246848
author Hu, Yanmin
Liu, Alexander
Vaudrey, James
Vaiciunaite, Brigita
Moigboi, Christiana
McTavish, Sharla M.
Kearns, Angela
Coates, Anthony
author_facet Hu, Yanmin
Liu, Alexander
Vaudrey, James
Vaiciunaite, Brigita
Moigboi, Christiana
McTavish, Sharla M.
Kearns, Angela
Coates, Anthony
author_sort Hu, Yanmin
collection PubMed
description Bacterial infections remain the leading killer worldwide which is worsened by the continuous emergence of antibiotic resistance. In particular, methicillin-sensitive (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and the latter can be difficult to treat. The traditional strategy of novel therapeutic drug development inevitably leads to emergence of resistant strains, rendering the new drugs ineffective. Therefore, rejuvenating the therapeutic potentials of existing antibiotics offers an attractive novel strategy. Plectasin, a defensin antimicrobial peptide, potentiates the activities of other antibiotics such as β-lactams, aminoglycosides and glycopeptides against MSSA and MRSA. We performed in vitro and in vivo investigations to test against genetically diverse clinical isolates of MSSA (n = 101) and MRSA (n = 115). Minimum inhibitory concentrations (MIC) were determined by the broth microdilution method. The effects of combining plectasin with β-lactams, aminoglycosides and glycopeptides were examined using the chequerboard method and time kill curves. A murine neutropenic thigh model and a murine peritoneal infection model were used to test the effect of combination in vivo. Determined by factional inhibitory concentration index (FICI), plectasin in combination with aminoglycosides (gentamicin, neomycin or amikacin) displayed synergistic effects in 76-78% of MSSA and MRSA. A similar synergistic response was observed when plectasin was combined with β-lactams (penicillin, amoxicillin or flucloxacillin) in 87–89% of MSSA and MRSA. Interestingly, no such interaction was observed when plectasin was paired with vancomycin. Time kill analysis also demonstrated significant synergistic activities when plectasin was combined with amoxicillin, gentamicin or neomycin. In the murine models, plectasin at doses as low as 8 mg/kg augmented the activities of amoxicillin and gentamicin in successful treatment of MSSA and MRSA infections. We demonstrated that plectasin strongly rejuvenates the therapeutic potencies of existing antibiotics in vitro and in vivo. This is a novel strategy that can have major clinical implications in our fight against bacterial infections.
format Online
Article
Text
id pubmed-4333121
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43331212015-02-24 Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus Hu, Yanmin Liu, Alexander Vaudrey, James Vaiciunaite, Brigita Moigboi, Christiana McTavish, Sharla M. Kearns, Angela Coates, Anthony PLoS One Research Article Bacterial infections remain the leading killer worldwide which is worsened by the continuous emergence of antibiotic resistance. In particular, methicillin-sensitive (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) are prevalent and the latter can be difficult to treat. The traditional strategy of novel therapeutic drug development inevitably leads to emergence of resistant strains, rendering the new drugs ineffective. Therefore, rejuvenating the therapeutic potentials of existing antibiotics offers an attractive novel strategy. Plectasin, a defensin antimicrobial peptide, potentiates the activities of other antibiotics such as β-lactams, aminoglycosides and glycopeptides against MSSA and MRSA. We performed in vitro and in vivo investigations to test against genetically diverse clinical isolates of MSSA (n = 101) and MRSA (n = 115). Minimum inhibitory concentrations (MIC) were determined by the broth microdilution method. The effects of combining plectasin with β-lactams, aminoglycosides and glycopeptides were examined using the chequerboard method and time kill curves. A murine neutropenic thigh model and a murine peritoneal infection model were used to test the effect of combination in vivo. Determined by factional inhibitory concentration index (FICI), plectasin in combination with aminoglycosides (gentamicin, neomycin or amikacin) displayed synergistic effects in 76-78% of MSSA and MRSA. A similar synergistic response was observed when plectasin was combined with β-lactams (penicillin, amoxicillin or flucloxacillin) in 87–89% of MSSA and MRSA. Interestingly, no such interaction was observed when plectasin was paired with vancomycin. Time kill analysis also demonstrated significant synergistic activities when plectasin was combined with amoxicillin, gentamicin or neomycin. In the murine models, plectasin at doses as low as 8 mg/kg augmented the activities of amoxicillin and gentamicin in successful treatment of MSSA and MRSA infections. We demonstrated that plectasin strongly rejuvenates the therapeutic potencies of existing antibiotics in vitro and in vivo. This is a novel strategy that can have major clinical implications in our fight against bacterial infections. Public Library of Science 2015-02-18 /pmc/articles/PMC4333121/ /pubmed/25692771 http://dx.doi.org/10.1371/journal.pone.0117664 Text en © 2015 Hu et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Hu, Yanmin
Liu, Alexander
Vaudrey, James
Vaiciunaite, Brigita
Moigboi, Christiana
McTavish, Sharla M.
Kearns, Angela
Coates, Anthony
Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
title Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
title_full Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
title_fullStr Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
title_full_unstemmed Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
title_short Combinations of β-Lactam or Aminoglycoside Antibiotics with Plectasin Are Synergistic against Methicillin-Sensitive and Methicillin-Resistant Staphylococcus aureus
title_sort combinations of β-lactam or aminoglycoside antibiotics with plectasin are synergistic against methicillin-sensitive and methicillin-resistant staphylococcus aureus
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333121/
https://www.ncbi.nlm.nih.gov/pubmed/25692771
http://dx.doi.org/10.1371/journal.pone.0117664
work_keys_str_mv AT huyanmin combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus
AT liualexander combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus
AT vaudreyjames combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus
AT vaiciunaitebrigita combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus
AT moigboichristiana combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus
AT mctavishsharlam combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus
AT kearnsangela combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus
AT coatesanthony combinationsofblactamoraminoglycosideantibioticswithplectasinaresynergisticagainstmethicillinsensitiveandmethicillinresistantstaphylococcusaureus